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Abstract
Background: Dipyrone (MET, metamizole) is a non-steroidal anti-inflammatory drug commonly used both in
human and in veterinary medicine. After oral administration, is broken down rapidly to metabolites which largely
retain the activity of the parent drug. Its metabolites have analgesic, antipyretic and anti-inflammatory effects.
Results: The subjects were eight healthy male Large White post-suckling piglets, weighing between 5.0 to 7.4 kg,
of ages 35 ± 10 days. The animals were administered MET (100 mg/kg) by an intramuscular (I.M.) injection. The
study calculated the value of several hemorheological parameters. Significant impact of MET treatment (p < 0.05)
was proven in case: activated partial thromboplastin time; ratio of activated partial thromboplastin time; hemoglobin;
hematocrit; mean corpuscular hemoglobin; mean corpuscular volume; red blood cells volume; white blood cells
volume; prothrombin time index.
Conclusions: In summation, our observations suggest that a piglet model is useful for studying the impact of MET on
hemorheological parameters.
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Background
Dipyrone (MET, metamizole) is a non-steroidal anti-
inflammatory drug commonly used both in human and
in veterinary medicine. In some countries dipyrone is
banned because of serious adverse effect [1]. But still the
drug is available in many countries depending on regis-
tration agency [2]. Like most anti-inflammatory drugs,
MET is not without adverse effects. MET, after oral ad-
ministration, is broken down rapidly to metabolites
which largely retain the activity of the parent drug.
These, 4 aminoantipirin (4AA) and 4 methylaminoanti-
pirin (4MAA), the pharmacokinetics of which were de-
scribed previously by Burmańczuk [3], have analgesic,
antipyretic and anti-inflammatory effects [4]. Still, the
sum of the side effects related to MET administration in-
cludes activities whose core has an effect on textured
blood components (neutrophil activation), and MET also
has impact on the functioning of the immune system
reactions (IgE mediated and specific T lymphocytes,
CD8+) [5, 6]. What is more, the use of the basophil-
activation test has revealed that the MET metabolites ac-
tivate basophils in a specific way in patients who are
hypersensitive to MET [7]. Still, agranulocytosis follow-
ing administration of MET in humans is a very rare
phenomenon, however, it has been confirmed that a sig-
nificant fall in the number of leukocytes after adminis-
tration of MET comes about in individual cases [8]. Such
agranulocytosis in humans is at a level of 2.4–14.5 ppm
[9]. MET, at higher doses, also affects catalase levels in
human red blood cells (RBC) [10]. Furthermore, dipyr-
one inhibits H2O2 forced erythrocytic membrane lipid
peroxidation [10], this means that it has a significant im-
pact on the physiology of the oxidation processes in hu-
man RBC. Yet, as up to 30% of all patients are
hypersensitive to pyrazolones after the administration of
MET (reacting through anaphylactic shock), the impact
of MET on hemorheological parameters has not been
fully explained [5–11].
For many years, the pig model has been one of the
more interesting ways of testing drugs destined for
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human administration. Indeed, such a model is widely
used in preclinical studies, particularly with respect to
the employment of miniature pigs [12]. It is important
to note that the pig and piglets is also considered as be-
ing one of the best non-rodent test-subjects in preclin-
ical therapeutic human monoclonal antibody studies
[13]. It is thought that large animals such as the pig,
rather than small animals, may be significantly better
models in the study of medicines destined for humans.
It can be said, then, that the pig model better reflects
human drug metabolism characteristics [14]. Hence,
current study verified the use of piglets as test system
which may reflect changes in hematological parameters
after a single I.M. injection of MET.
Methods
For presented study dipyrone was selected as an agent
that inhibits the platelet aggregation [15]. Moreover
single-dose dipyrone have similar efficacy to other anal-
gesics used in postoperative pain [16]. Single dose study
was proposed due to the fact that single dose analysis
could indicate the choice of dosing interval and dose
[17]. Consequently the studies with multiple dose should
be preceded by single dose study to avoid mistakes in
optimization of multiple dose studies.
Animals
The subjects were eight healthy male Large White post-
suckling piglets, weighing between 5.0 to 7.4 kg, of ages
35 ± 10 days. The piglets were deprived of food for 8 h
prior to the commencement of the experiment, while
water was available ad libitum. The animals were ad-
ministered MET (100 mg/kg; Biovetalgin, 500 mg/mL,
Biowet, Drwalew, Poland) by an I.M. injection.
In humans, the standard dipyrone dosage is 0.5 to
1.0 g, up to four times a day [4]. Our study determined
that the typical dose which is given to piglets weighing
about 5 kg was similar to that which is commonly ad-
ministered to humans weighing about 70 kg (0.5 g per
animal). After I.M. drug administration, blood was sam-
pled from the jugular vein (2 mL) at intervals of 0 before
dosing (control) 0.25, 0.50, 0.75, 1, 2, 4, 6, 8, 10, 12, 24,
48, 72 h into heparinized tubes, by vacutainer (BD Vacu-
tainer® Safety- Lok). The blood plasma 4MAA and 4AA
concentrations were subsequently analyzed by high pres-
sure liquid chromatography [18]. The study protocol
was approved by the ethics committee of the University
of Life Sciences, Lublin (84/2015).
Hemorheological parameters
The taken blood samples were analyzed for basic indica-
tors of blood counts (white blood cells – WBC). More-
over, the following parameters were determined using an
automated hematology analyzer – Abacus Junior Vet
(Diatron Group, Hungary): APTT – activated partial
thromboplastin time; APTTratio – ratio of activated par-
tial thromboplastin time; Hb – hemoglobin; Hct –
hematocrit; MCH – mean corpuscular hemoglobin;
MCV – mean corpuscular volume; RBC – red blood
cells volume; WBC – white blood cells volume; PT –
prothrombin time index; MCHC – mean corpuscular
hemoglobin concentration; Plt – platelets.
Platelet function testing was performed by way of
employing an automated analyzer - PFA-200 INNO-
VANCE® Analyzer (Healthineers Siemens, Germany), to
assess rates of platelet activation: ADP-dependent and
COX-1 dependent pathway. The study used citrated
whole blood analysis via two types of cartridges dubbed
with the corresponding agonist of platelet activation: a
Collagen/ADP Test Cartridge (collagen type I with ad-
enosine diphosphate) and Collagen/EPI Test Cartridge
(type I collagen and epinephrine bitartrate) (Dade
Behring, Germany). The study was performed within
15 min of the collection of blood and platelet activation
was measured by quantity of time needed to complete
closure of the micro-holes of the cartridge membrane
and the cessation of blood flow – the so-called ‘occlu-
sion time’ (CT – closure time). Herein, a shorter CT
means a higher degree of platelet activity, whereas an
elongated CT indicates their lower activity [19–23].
The condition (status) of plasma coagulation was
assessed by way of the maintenance of the hemostasis
tests: the prothrombin time and APTT. Fibrinogen con-
centration was also determined by prothrombin time
dependent method using thromboplastin [24, 25]. The
study employed an automatic optical coagulometer Biok-
sel 6000 (Bio-Ksel, Poland). The reagents used were sup-
plied by the same company: for the determination of
prothrombin time and fibrinogen concentration - Bio-
Ksel PT plus, and for APTT measurement - Bio-Ksel
System APTTs. All assays were performed in fresh plate-
let poor citrated plasma, separated from the citrated
blood no more than 1 h from (after) its collection. Blood
spinning (centrifugation) was carried out at 21 °C at
1500 × g. For calibration the coagulometer used a freeze-
dried human standard plasma (Bio-Ksel, Poland). The
results for PT and APTT are given in seconds, and the
PT and international normalized ratio for prothrombin
time and ratio for APTT were calculated [19, 20, 24, 25].
Pharmacodynamic, pharmacokinetics and statistical
analysis
The pharmacodynamics calculations were performed
using Phoenix® WinNonlin® 6.4 software (Certara L.P.,
US), while statistical analyses were carried out by way of
GraphPad Prism® 6.01 software (GraphPad Software Inc.,
US). The aforementioned utilized pharmacokinetic pa-
rameters were those described earlier by Burmańczuk et
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al [3]. The pharmacodynamic calculations were based on
the area under the effect curve (AUEC) analysis. This is
calculated via the linear trapezoidal approach, and it is
ascertained firstly for its baseline (B) in a range
beginning 36 h prior to administration and extending to
a time equal to zero just prior to MET administration,
and then for a curve relating the effect after drug admin-
istration (A) in the range of 0–72 h after MET adminis-
tration. Herein, the time (36 h↔0 h↔72 h) ratio of
AUEC effect/baseline (A/B) was produced using the
formula. Differences between AUEC baseline (B/36)
and the curve relating the effect (A/72) were consid-
ered statistically significant at p < 0.05. The level of
significance was determined by way of applying the
paired Student’s t test.
The study also sought to bring about an understanding
of the comprehensive relationship between hemorheolo-
gical parameters and the concentration of metabolites.
In our work, to validate the relationship between the
concentrations of metabolites and the hemorheological
parameters, the live-one-out (LOO) procedure was
utilized [26–30]. Moreover, the squared cross-validated
correlation coefficient (Q2) parameter and difference be-
tween Q 2 and squared Pearson correlation coefficient
(R2) was calculated so as to assess the the measure of in-
ternal performance and model predictive-ability. In
addition, the Total sum of squares was ascertained (SS).
Here, a value closer to 0 indicates that the model has a
smaller random error, and the fit will be more optimal
for prediction. Beyond the aforementioned, we deter-
mined the predicted residual sums of squares (PRESS).
A lowest value of PRESS indicates a not-over-fitted
model. Finally, the difference between the fitting and the
predictive ability of the models was analyzed by calculat-
ing the difference between the asymptotic squared
cross-validated correlation coefficient (Q 2asym) and Q
2.
Herein, a minimal validation criteria is established so to
assess whether the adopted model is in line with the re-
quirements of the OECD. In this: Q2asym - Q
2 > 0 < 1 and
Q2 ≥ 0.65, while R2 ≥ 0.85, and Q2 - R2 < 0 [27, 28]. The
only model that meets all the criteria is, at the same
time, qualified as being verified positively, as well as be-
ing fully predictive.
Results
The study calculated the value of several hemorheolo-
gical parameters (Fig. 1; Additional file 1). Table 1 re-
veals those for which a significant difference was
found between AUEC as determined for baseline, and
the curve illustrating the effect obtained after MET
injection. Herein, Plt after administration showed a
marked increase and then a decrease, with Plt peak-
ing at 10 h after MET administration (p < 0.05), and
the value of Plt 24 h after administration returning to
the baseline level. With regard to fibrinogen, after the
administration of the drug, our results showed a sig-
nificant decline, which peaked at 6 h after administra-
tion of MET (p < 0.05). Fibrinogen levels, however,
returned to baseline levels 24 h after administration
of MET. It was also confirmed that a significant cor-
relation exists between the level of fibrinogen and
WBC (R2 = 8.355, p < 0.05). The other parameters ob-
tained after administration of MET showed no statis-
tically significant change (baseline: effect).
The between-animal variability parameters that were
observed, expressed the percent of relative standard de-
viation (RSD%) for baseline, and then separately for the
data which were obtained after administration of the
drug. For MCV and PT, the RSD% curves obtained after
drug administration were lower than or equal to the
Table 1 Dynamics of changes in blood parameters expressed as minimum, maximum, and area under the curve effect (AUEC) in
piglets, after a single I.M. administration of dipyrone at a dose of 100 mg/kg
Blood
analysis
Dynamic range of effect minimal
to maximal (M; SD)






APTT 113.59; 25.95 45.14; 11.04 4766.87; 542.43 2968.43; 588.85 0.197 0.0207
APTTratio 3.36; 0.77 1.33; 0.33 140.69; 16.01 86.38; 17.14 0.186 0.0259
Hb 12.35; 0.58 9.14; 0.49 628.56; 74.74 450.96; 20.44 0.303 0.0001
Hct 36.32; 1.63 26.64; 1.70 1808.43; 213.89 2586.93; 58.18 0.650 0.0001
MCH 19.65; 0.88 17.58; 0.91 1198.07; 139.58 707.33; 33.62 0.153 0.0046
MCV 58.00; 2.60 51.25; 3.53 3440.34; 406.96 2019.75; 113.64 0.148 0.0052
RBC 6.56; 0.33 5.22; 0.37 362.90; 42.88 229.96; 10.74 0.211 0.0001
WBC 24.67; 2.14 14.71; 1.76 1267.83; 179.64 476.63; 41.72 −0.330 0.0006
PT 95.00; 6.08 77.25; 3.67 5164.33; 699.57 3207.75; 406.96 0.195 0.0076
M arithmetic mean, SD standard deviation, A area under effect curve at time 0 to 72 h (after treatment), B area under effect curve at baseline (time between 36 h
before treatment and time zero), A/B ratio calculated from A and B value, APTT activated partial thromboplastin time, APTTratio ratio of activated partial
thromboplastin time, Hb hemoglobin (g/dL), Hct hematocrit (%), MCH mean corpuscular hemoglobin (pg), MCV mean corpuscular volume (fL), RBC red blood cells
volume (×1012 L), WBC white blood cells volume (×109 L), PT prothrombin time index (%); p-value – calculated between A/72 and B/36
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RSD% obtained for baseline. These values were, for
MCV and PT, respectively (baseline:effect), 12.38% vs.
7.26%, and 5.02% vs. 5.02%. For all the other parameters
listed in Table 1, the RSD% of baseline ranged from 4.44
to 20.41, and in the case of the curves which covered
the effect of RSD%, these ranged from 5.02 to 26.34.
As presented in the form of an arithmetic expression
PT + [(Hb +Hct)/(RBCATT Pr atio)] (Fig. 2), there was a
Fig. 1 Dynamics of changes in blood parameters after a single I.M. administration of dipyrone in piglets (n = 8) at a dose of 100 mg/kg. Changes
in: white blood cells volume (a), red blood cells volume (b), hemoglobin (c), mean corpuscular volume (d), mean corpuscular hemoglobin (e),
prothrombin time index (f), activated partial thromboplastin time (g), hematocrit (h). The period between -36 h and the value 0 represents the
baseline - the value before drug administration. APTT – activated partial thromboplastin time (s); APTTratio- ratio of activated partial thromboplastin time;
Hb – hemoglobin (g/dL); Hct – hematocrit (%); MCH – mean corpuscular hemoglobin (pg); MCV – mean corpuscular volume (fL); RBC – red blood cells
volume (× 1012 L); WBC – white blood cells volume (× 109 L); PT – prothrombin time index (%); dashed line – arithmetic mean of baseline value
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significant correlation between the concentration of
4MAA and hemorheological parameters. These relation-
ships are statistically significant (p < 0.001). The valid-
ation parameters that were determined through our
work according to the LOO 4MAA↔ PT + [(Hb +
Hct)/(RBCATT Pr atio)] generated the following values:
Q2asym-Q
2 = 0,063, Q2 = 0.8274, R2 = 0.8905, Q2-R2 =
0.0631, SS = 1573.36, PRESS = 271.57. At the same time,
our work did not confirm the existence of the same de-
pendency relation to 4AA↔ PT + [(Hb +Hct)/(RBCATT Pr
atio)] (p > 0.05).
Discussion
The aim of the current study was a verification of piglets
as a model reflecting changes in hematological parameters
after a single I.M. injection of MET. Thrombocytopenia
and pancytopenia after MET administration is related to
bone marrow suppression. Mechanism covers drug-
dependent suppression of the growth of myeloid progeni-
tors, primitive multipotential progenitors and erythroid
progenitors [31, 32]. As in humans, the piglet model dem-
onstrates that MET and its metabolites contribute to sig-
nificant increase of neutrophil count, which represents a
large fraction of the total number of WBC. Similar effects
were found in rats [33]. In dogs, however, there was no
significant MET effect in level of WBC when given at a
dose of 25 mg/kg [34]. With regard to piglet model, the ef-
fect of the MET on WBC also manifests the fluctuating
course of the curve reporting on the effect. Herein, WBC
returns to the values obtained with the baseline MET con-
centration, as well as that of its metabolites, which decline
in the blood, 72 h after administration.
What is more, a significant decrease in RBC and Hct
after the administration of MET is reported in Rhamdia
sp. based studies [35]. In addition, in dog-based studies,
a decrease in RBC counts were noted after MET admin-
istration [4], while in rats, RBC count rose slightly [33].
In the case of proposed piglet model, RBC counts de-
crease through 72 h after dosing. At the same, no con-
firmation is evident in this interval for any tendency to
return to baseline - as the slope of the curve relating the
effect is maintained after 4 h from the administration of
the drug, at a constant level up to 72 h. Thus, it con-
firmed the possibility of utilizing breeding piglets for
tracking model purposes in assessing the impact of MET
and its metabolites on the physiology of RBC. This
process also reflects the decrease in Hb, as the dynamics
of changes in relation to the RBC and Hb are similar.
Following administration of MET, in the case of
piglets, as well as in humans, Hct levels significantly
decrease [36]. Yet, in rat-based studies, MET adminis-
tration induced a slight fall in Hct [33], while in dogs,
no MET-induced effects were seen in Hct levels at a
dose of 25 mg/kg [34]. Of note, the observed variabil-
ity is substantial, however, the observed decrease is
significant (p < 0.05).
Hb after the administration of MET also has been seen
to drop significantly, and the process is characterized by
the extremely low volatility of observed data. In both rat
and dog-based studies, Hb levels were seen to fall [4, 33].
Regarding piglet model, Hb virtually retains its dynamics
between 12 and 72 h after administration.
As shown in the data generated within our study, Hct,
RBC and Hb are complementary, and in this case, con-
firm the predictability of the proposed model. Indeed,
between RBC and the sums of Hct and Hb, a strong
significant correlation is seen (R2 = 0.9500, p < 0.05).
In rat-based studies, the value of MCV was seen to
drop after MET administration [33]. A similar situation
was seen in studies based on utilizing piglets. With re-
gard to MCV + PT, and 4MAA concentrations, up to
48 h after drug administration, a significant linear rela-
tionship was evident (R2 = 0.8810, p < 0.05). In contrast,
the same relationship with respect to 4AA was not sig-
nificant. This implies that MET administration has a dir-
ect impact on 4MAA levels (MCV + PT), and, therefore,
is essential to the expression of 4MAA.
A single administration of MET (at a dose of 1 g) is
known to not significantly affect APTT in humans [37].
However, as shown via the piglet model, a high level of
significance regarding MET administration and APTT
actually does exist. After 6 h post-dosage, the value of
APTT drops significantly. The curve relating the effect
of the drug, in this case, reveals the fluctuating course of
effect, as between 24 and 72 h post-administration of
MET, the value of APTT declines and does not return to
Fig. 2 The relationship between the concentration of 4 methylamino
antipyrin (4 MAA) and the hemorheological parameter image changes -
presented in the form of an arithmetic expression: PT+ [(Hb+Hct)/
(RBCATT Pr atio)]. APTTratio – ratio of activated partial thromboplastin time;
Hb – hemoglobin (g/dL); Hct – hematocrit (%); RBC – red blood cells
volume (× 1012 L); PT – prothrombin time index (%)
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the original level. The fluctuating nature of the afore-
mentioned changes may be associated with the impact
of MET on the process of plasma recalcification [38],
just as administration of MET is recognized as having a
relaxation effect on the smooth muscle [39].
In the course of the analysis, we have confirmed the
existence of a 4MAA dependence↔ PT + [(Hb +Hct)/
(RBCATT Pr atio)]. This relationship predictive value with
respect to 4MAA, confirms the performed validation
procedure. This means that hemorheological parameters
after administration of MET may reflect the concentration
of 4MAA in piglet blood plasma. Of note, the mechanism
of the effect of the 4MAA on hemorheological parameters
is significantly different from that of 4AA.
Conclusions
In our study, all the piglets showed tolerance to the dos-
ages given out, and such high doses allowed to analyze
precisely the impact of MET on hemorheological param-
eters. In our study, nine parameters showed significant
differences to baseline. Most deleterious effect on blood
parameters observed in current study were deep and
prolonged decrease of PT and Hb concentration con-
nected with decreased number of RBC. As in humans,
the piglet model shown that MET and its metabolites
contribute to significant increase of number of neutro-
phils. The resulting image changes converge to the ob-
servations that were noticed in humans. To sum up, our
observations suggest that a piglet model is useful for
studying MET and its metabolites impact on hemorheo-
logical parameters.
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